MapLight Insider Sell‑Offs: Tax Moves, ADC Breakthrough & Q3 2026 Phase‑2 Impact
MapLight Therapeutics insider sell‑offs hit 4 % of market cap, yet stock stays near 52‑week high as FDA approves first‑in‑class CD47 ADC; Q3 2026 Phase 2 results could lift or dampen valuation.
4 minutes to read